Genelux Corporation (GNLX)
Genelux Corporation operates in the Biotechnology industry of the Healthcare sector, headquartered in Westlake Village, CA, US. The stock last traded at $2.65, down 2.57% on the session, giving a market capitalisation of $118.8M. On trailing twelve-month figures it carries a trailing P/E of -3.01, a net margin of -397225.0%. Its beta of 0.59 implies it has historically moved less than the broad market.
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.
Genelux Corporation is most often compared with the following Healthcare names: